Open AccessInitial treatment response among HIV subtype F infected patients who started antiretroviral therapy based on integrase inhibitors
Author(s) -
Purificación CidSilva,
Luis MargusinoFramiñán,
Vanesa BalboaBarreiro,
Isabel MartínHerranz,
Ángeles CastroIglesias,
Berta Pernas,
Josep M Llibre,
Eva Poveda
Publication year - 2018
Publication title -
aids
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.195
H-Index - 216
eISSN - 1473-5571
pISSN - 0269-9370
DOI - 10.1097/qad.0000000000001679
Subject(s) - integrase , integrase inhibitor , antiretroviral therapy , virology , medicine , lentivirus , human immunodeficiency virus (hiv) , sida , viral disease , viral load
: HIV-1 subtype B (54.4%) and subtype F (27.2%) are the most prevalent variants in patients who started antiretroviral therapy including an integrase inhibitor in the last 2 years in Northwest Spain. Virological response rates to antiretroviral therapy based on integrase inhibitor were significantly lower among F subtypes compared with B subtypes at weeks 12 (25.0% vs. 75.0%) and 24 (59.1% vs. 95.0%). Subtype F was independently associated with virological response at 24 weeks [odds ratio 11.8 (95% confidence interval 1.1-119.9); P = 0.037].